STING1 and ovarian carcinoma: Recently, PARP inhibition by olaparib was found to induce robust innate and adaptive immune responses in a BRCA-deficient murine ovarian cancer model, as well as enhanced benefit in combination with anti-PD-1, via cytosolic DNA sensing and activation of the stimulator of interferon genes (STING) pathway.94,95 Conversely, PARPi may also interfere with healthy immune function.